Preclinical Molecular PET-CT Imaging Targeting CDCP1 in Colorectal Cancer.
Animals
Antigens, Neoplasm
/ genetics
Cell Adhesion Molecules
/ genetics
Colorectal Neoplasms
/ diagnostic imaging
Gene Expression Regulation, Neoplastic
/ drug effects
HCT116 Cells
Heterografts
Humans
Ligands
Mice
Positron Emission Tomography Computed Tomography
Radioisotopes
/ pharmacology
Zirconium
/ pharmacology
Journal
Contrast media & molecular imaging
ISSN: 1555-4317
Titre abrégé: Contrast Media Mol Imaging
Pays: England
ID NLM: 101286760
Informations de publication
Date de publication:
2021
2021
Historique:
received:
02
07
2021
accepted:
05
09
2021
entrez:
8
10
2021
pubmed:
9
10
2021
medline:
25
2
2022
Statut:
epublish
Résumé
Colorectal cancer (CRC) is the third most common malignancy in the world, with 22% of patients presenting with metastatic disease and a further 50% destined to develop metastasis. Molecular imaging uses antigen-specific ligands conjugated to radionuclides to detect and characterise primary cancer and metastases. Expression of the cell surface protein CDCP1 is increased in CRC, and here we sought to assess whether it is a suitable molecular imaging target for the detection of this cancer. CDCP1 expression was assessed in CRC cell lines and a patient-derived xenograft to identify models suitable for evaluation of radio-labelled 10D7, a CDCP1-targeted, high-affinity monoclonal antibody, for preclinical molecular imaging. Positron emission tomography-computed tomography was used to compare zirconium-89 (
Identifiants
pubmed: 34621145
doi: 10.1155/2021/3153278
pmc: PMC8455202
doi:
Substances chimiques
Antigens, Neoplasm
0
CDCP1 protein, human
0
Cell Adhesion Molecules
0
Ligands
0
Radioisotopes
0
Zirconium
C6V6S92N3C
Zirconium-89
NTM296JU95
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3153278Informations de copyright
Copyright © 2021 Tahleesa J. Cuda et al.
Déclaration de conflit d'intérêts
Yaowu He, Thomas Kryza, Simon Puttick, and John Hooper are inventors on a Patent Filing for 10D7-based CDCP1-targeted biomolecules.
Références
Cell Oncol (Dordr). 2015 Feb;38(1):49-64
pubmed: 25248503
Exp Biol Med (Maywood). 2015 Dec;240(12):1764-73
pubmed: 25956680
Curr Top Med Chem. 2015;15(8):795-819
pubmed: 25732787
Gastroenterology. 2013 Sep;145(3):636-46.e5
pubmed: 23747337
Circ Cardiovasc Imaging. 2018 Feb;11(2):e005355
pubmed: 29449411
Cancer Sci. 2009 Nov;100(11):2188-92
pubmed: 19659515
Contrast Media Mol Imaging. 2019 Sep 22;2019:8946729
pubmed: 31598114
Updates Surg. 2016 Mar;68(1):7-11
pubmed: 27067591
Anticancer Agents Med Chem. 2018;18(1):74-86
pubmed: 28425855
Bioconjug Chem. 2009 May 20;20(5):825-41
pubmed: 19125647
Ann Surg Oncol. 2015 Dec;22(13):4335-43
pubmed: 25820997
Cancer Res. 2021 May 1;81(9):2259-2269
pubmed: 33509939
Theranostics. 2018 Jul 30;8(16):4295-4304
pubmed: 30214621
Pharmacol Res. 2017 Jan;115:87-95
pubmed: 27865762
Mol Imaging Biol. 2017 Apr;19(2):163-182
pubmed: 27812924
Nucl Med Biol. 2018 Sep - Oct;64-65:1-7
pubmed: 30015090
Oncogene. 2020 Jan;39(1):219-233
pubmed: 31471585
J Clin Toxicol. 2014 Aug;4(4):
pubmed: 26539323
Eur J Pharm Biopharm. 2009 Mar;71(3):409-19
pubmed: 19070661
J Nucl Med. 2003 Oct;44(10):1663-70
pubmed: 14530484
J Magn Reson Imaging. 2017 Jan;45(1):21-35
pubmed: 27346172
Ann ICRP. 2015 Sep;44(2):5-188
pubmed: 26494836
Theranostics. 2020 Jun 25;10(17):7921-7924
pubmed: 32685029
IARC Monogr Eval Carcinog Risks Hum. 2001;78(Pt 2):1-559
pubmed: 11421248
J Nucl Med. 2007 Jun;48(6):18N, 21N
pubmed: 17536102
Theranostics. 2020 Jan 12;10(5):2095-2114
pubmed: 32104500
Int J Mol Sci. 2016 Dec 28;18(1):
pubmed: 28036044
Oncogene. 2016 Jan 28;35(4):468-78
pubmed: 25893298
Crit Rev Oncol Hematol. 2013 Feb;85(2):121-35
pubmed: 22762963
Cancer Lett. 2012 Feb 28;315(2):97-111
pubmed: 22104729
Semin Radiat Oncol. 2011 Apr;21(2):88-100
pubmed: 21356477
J Biol Chem. 2011 Dec 9;286(49):42303-42315
pubmed: 21994943
EJNMMI Radiopharm Chem. 2019 Nov 6;4(1):29
pubmed: 31696402
J Nucl Med. 2017 May;58(5):689-696
pubmed: 28385796
J Nucl Med. 2017 Sep;58(Suppl 2):83S-90S
pubmed: 28864618
Radiology. 2010 Dec;257(3):674-84
pubmed: 20829538
Mol Cancer Res. 2009 Aug;7(8):1197-211
pubmed: 19671673
Theranostics. 2020 Mar 4;10(9):4116-4133
pubmed: 32226543
Lancet. 2014 Apr 26;383(9927):1490-1502
pubmed: 24225001
JAMA. 2005 Feb 16;293(7):855-62
pubmed: 15713776
Future Oncol. 2015;11(7):1083-91
pubmed: 25804123
Semin Oncol. 2000 Dec;27(6 Suppl 12):62-73
pubmed: 11226002
Nucl Med Biol. 2020 May - Jun;84-85:63-72
pubmed: 32135473
J Pharm Sci. 2010 Feb;99(2):1028-45
pubmed: 19569059
J Control Release. 2016 Oct 28;240:267-286
pubmed: 26772878
J Vis Exp. 2015 Feb 12;(96):
pubmed: 25741890
IUBMB Life. 2009 Jul;61(7):723-30
pubmed: 19514048
J Nucl Med. 2014 Apr;55(4):622-8
pubmed: 24639459
Nagoya J Med Sci. 2017 Nov;79(4):527-543
pubmed: 29238109
Biomed Res Int. 2014;2014:203601
pubmed: 24991539
Head Neck. 2010 May;32(5):666-78
pubmed: 19827126
Mol Imaging Biol. 2018 Oct;20(5):683-695
pubmed: 30084044
Sci Rep. 2018 Jan 12;8(1):633
pubmed: 29330552
Exp Physiol. 2020 Sep;105(9):1459-1466
pubmed: 32666546